Sacituzumab Govitecan for the Treatment of HR+/HER2- Breast Cancer in Heavily Pre-treated Patients
نویسندگان
چکیده
Metastatic hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) breast cancer survival outcomes have improved significantly; however, once endocrine resistance develops, response rates to systemic treatments are limited. Within the developing field of antibody–drug conjugates, TROPiCS-02 study showed a significant improvement in progression-free with sacituzumab govitecan compared physician’s choice chemotherapy patients endocrine-resistant, metastatic, HR+/HER2- cancer. Additionally, overall similarly (14.4 months versus 11.2 months, respectively). We discuss role and its practice, looking at direct impact it has metastatic
منابع مشابه
Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer.
BACKGROUND/AIM Recurrent triple-negative breast cancer (TNBC) patients have poor prognoses and limited treatment options, especially after progression during prior chemotherapy. The present study aimed to determine the impact of itraconazole with chemotherapy in these patients. PATIENTS AND METHODS Medical records of recurrent TNBC patients receiving itraconazole with chemotherapy between 200...
متن کاملTreatment of Heavily Pre-treated Metastatic Breast Cancer with Eribulin: First local experience in Sabah.
There are many options in the treatment of heavily pretreated metastatic breast cancer however none of the therapeutic agents have shown promising improvement of survival with good toxicity profile. Eribulin is a novel nontaxane microtubule dynamics inhibitor. Two recent clinical trial showed that Eribulin improves progression-free and overall survival in this subset of patients. We report our ...
متن کاملWeekly non-pegylated liposomal doxorubicin chemotherapy in heavily pre-treated patients with metastatic breast cancer.
BACKGROUND Due to its low cardiac toxicity, non-pegylated liposomal doxorubicin (NPLD) may represent an attractive therapeutic option as salvage therapy for patients with metastatic breast cancer who have already received anthracycline-based chemotherapy. PATIENTS AND METHODS We retrospectively reviewed 47 consecutive patients with metastatic breast cancer treated with NPLD at our Institution...
متن کاملthe study of aaag repeat polymorphism in promoter of errg gene and its association with the risk of breast cancer in isfahan region
چکیده: سرطان پستان دومین عامل مرگ مرتبط با سرطان در خانم ها است. از آنجا که سرطان پستان یک تومور وابسته به هورمون است، می تواند توسط وضعیت هورمون های استروئیدی شامل استروژن و پروژسترون تنظیم شود. استروژن نقش مهمی در توسعه و پیشرفت سرطان پستان ایفا می کند و تاثیر خود را روی بیان ژن های هدف از طریق گیرنده های استروژن اعمال می کند. اما گروه دیگری از گیرنده های هسته ای به نام گیرنده های مرتبط به ا...
15 صفحه اولEffective panitumumab treatment in patients with heavily pre-treated metastatic colorectal cancer: a case series.
In heavily pre-treated patients with metastatic colorectal cancer (mCRC), further chemotherapy has not demonstrated efficacy. Panitumumab is indicated as monotherapy treatment of epidermal growth factor receptor (EGFR)-expressing, Kirsten (K)-RAS wild-type metastatic colorectal cancer after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-containing regimens. However, panitumumab has n...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Touch reviews in oncology & haematology
سال: 2023
ISSN: ['2752-5481']
DOI: https://doi.org/10.17925/ohr.2023.19.1.1